Skip to content

Co infection of carbapenem resistant Klebsiella pneumoniae and Acinetobacter baumannii in immunosuppressed lung transplantation based on metagenomic second-generation sequencing

Co infection of carbapenem resistant Klebsiella pneumoniae and Acinetobacter baumannii in immunosuppressed lung transplantation based on metagenomic second-generation sequencing

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112779
Enrollment
Unknown
Registered
2025-11-19
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Co infection of carbapenem resistant Klebsiella pneumoniae and Acinetobacter baumannii in immunosuppressed lung transplantation

Interventions

Coexistent infection group:None
CRKP infection group:None
CRAB infection group:None

Sponsors

Wuxi People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Lung transplant recipients aged 18 years or older; 2. Evidence of lower respiratory tract infection, with at least two of the following: abnormal body temperature (greater than 38.5°C or less than 36.5°C), or increased purulent respiratory secretions or other infection symptoms, or abnormal white blood cell count (greater than 12×10^9/L or less than 4×10^9/L), significantly elevated CRP, or pulmonary imaging (chest CT or chest X-ray) suggesting new inflammatory lesions or progressive infiltrates in the lungs; 3. Those who meet the above criteria and require bronchoscopy for bronchoalveolar lavage examination.

Exclusion criteria

Exclusion criteria: 1. Unstable vital signs; 2.Consciousness disorders, cerebrovascular accidents, stroke; 3.Septic shock/ARDS; 4. Acute coronary syndrome; 5. Recently, there has been severe hemoptysis; 6. Severe bleeding tendency; 7.Smoking; 8.Severe impairment of lung function, accompanied by severe hypoxemia, and inability to tolerate bronchoscopy examination.

Design outcomes

Primary

MeasureTime frame
Drug sensitivity test;

Secondary

MeasureTime frame
Microbial diversity of the microbiome;

Countries

China

Contacts

Public ContactWang Hongmei

Wuxi People's Hospital

whmwxrmyy@163.com+86 510 85351512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026